Sunshine Biopharma Inc.
SBFM
Positions held
Your positionsSBFM isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $1.64M | Enterprise value | -$11.67M | Trailing P/E | — | Forward P/E | 0.00 |
| PEG | — | Price / book | 0.03 | Beta | 1.35 | Dividend yield | 0.00% |
| Revenue growth | -1.6% | Earnings growth | — | Gross margin | 30.3% | Operating margin | -17.4% |
| Profit margin | -16.5% | ROE | -21.9% | ROA | -9.9% | Debt / equity | 0.02 |
| Current ratio | 5.46 | Free cash flow | -$2.01M | Analyst recommendation | none | Mean target | $56.00 |
| 52w high | $24.30 | 52w low | $0.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $9.3M | $8.1M | $8.6M | $9.4M | $9.4M | — |
| Op margin | -17.4% | -17.3% | -19.3% | -5.6% | -10.6% | — |
| Net income | -$1.6M | -$1.2M | -$2.1M | -$0.9M | -$1.8M | — |
| Gross margin | 26.2% | 27.0% | 35.3% | 32.6% | 36.4% | — |
| Gross profit | $2.4M | $2.2M | $3.0M | $3.1M | $3.4M | — |
| Operating income | -$1.6M | -$1.4M | -$1.7M | -$0.5M | -$1.0M | — |
- Revenue +15% vs prior quarter ($9.3M vs $8.1M).
- Gross margin 26.2% (was 27% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | — |
| Op margin | -12.3% | -16.7% | -19.9% | -199.6% | — |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | — |
| Gross margin | 33.8% | 30.6% | 34.6% | 39.0% | — |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | — |
| Operating income | -$4.5M | -$5.8M | -$4.8M | -$8.7M | — |
Headlines — watch
• [WARN · balance sheet] Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns
News
2026-10-08 · Sunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution Concerns
2026-10-08 · BC-Most Active Stocks
2026-10-08 · Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
2026-10-07 · BC-Most Active Stocks
2026-09-24 · Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know
2026-09-24 · Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care Portfolio
2026-09-16 · Sunshine Biopharma Advances Lead Coronavirus Drug Candidate into IND-Enabling Studies
2026-09-16 · EXCLUSIVE: Sunshine Biopharma Advances 'Differentiated Antiviral Candidate' to IND-Enabling Studies
2026-08-31 · Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions
2026-08-26 · A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
2026-08-26 · EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Price (daily)
Full chart · RSI · MACD · patterns